Dyne Therapeutics, Inc. (DYN)

Market Cap	1.09B
Revenue (ttm)	n/a
Net Income (ttm)	-367.13M
Shares Out	113.67M
EPS (ttm)	-3.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,644,805
Open	10.07
Previous Close	10.05
Day's Range	9.54 - 10.20
52-Week Range	6.36 - 47.45
Beta	1.16
Analysts	Strong Buy
Price Target	43.60 (+355.59%)
Earnings Date	Aug 11, 2025

About DYN

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and i...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 17, 2020
• Employees: 191
• Stock Exchange: NASDAQ
• Ticker Symbol: DYN
• Website: https://www.dyne-tx.com

Analyst Forecast

According to 15 analysts, the average rating for DYN stock is "Strong Buy." The 12-month stock price forecast is $43.6, which is an increase of 355.59% from the latest price.

Price Target

$43.6

(355.59% upside)

Analyst Consensus: Strong Buy